Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis.

Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ, Ling XL, Ma SC.

J Mol Histol. 2014 Oct;45(5):533-40. doi: 10.1007/s10735-014-9574-3. Epub 2014 May 10.

PMID:
24816798
2.

Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.

Lin Q, Guo L, Lin G, Chen Z, Chen T, Lin J, Zhang B, Gu X.

Cancer Epidemiol. 2015 Aug;39(4):539-44. doi: 10.1016/j.canep.2015.05.010. Epub 2015 Jun 27.

PMID:
26123318
3.

Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.

Rouanne M, Adam J, Goubar A, Robin A, Ohana C, Louvet E, Cormier J, Mercier O, Dorfmüller P, Fattal S, de Montpreville VT, Lebret T, Dartevelle P, Fadel E, Besse B, Olaussen KA, Auclair C, Soria JC.

BMC Cancer. 2016 Jul 15;16:483. doi: 10.1186/s12885-016-2541-5.

4.

Overexpression of osteopontin, αvβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer.

Jin Y, Tong DY, Chen JN, Feng ZY, Yang JY, Shao CK, Li JP.

PLoS One. 2012;7(10):e48575. doi: 10.1371/journal.pone.0048575. Epub 2012 Oct 31.

5.

Osteopontin is a prognostic biomarker in non-small cell lung cancer.

Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM.

BMC Cancer. 2013 Nov 11;13:540. doi: 10.1186/1471-2407-13-540.

6.

[Over-expression of osteopontin in non-small cell lung cancers: its clinical significance].

Hu Z, Xiao T, Lin DM, Guo SP, Zhang ZQ, Di XB, Cheng SJ, Gao YN.

Zhonghua Zhong Liu Za Zhi. 2007 Aug;29(8):591-5. Chinese.

PMID:
18210878
7.

Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.

Xuan ZX, Zhang S, Yuan SJ, Wang W, Yu J.

World J Surg Oncol. 2016 Sep 2;14(1):237. doi: 10.1186/s12957-016-0992-4.

8.

The expression of hypoxia-inducible factor-1α and its clinical significance in lung cancer: a systematic review and meta-analysis.

Ren W, Mi D, Yang K, Cao N, Tian J, Li Z, Ma B.

Swiss Med Wkly. 2013 Sep 6;143:w13855. doi: 10.4414/smw.2013.13855. Review.

9.

Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density.

Yu TT, Han ZG, Shan L, Tao J, Zhang T, Yuan SF, Shen HL.

Asian Pac J Cancer Prev. 2014;15(1):29-32.

10.

Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review.

Luo Z, Wu RR, Lv L, Li P, Zhang LY, Hao QL, Li W.

Int J Clin Exp Pathol. 2014 Jun 15;7(7):3632-46. eCollection 2014. Review.

11.

Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma.

Štemberger C, Matušan-Ilijaš K, Avirović M, Bulat-Kardum L, Ivančić A, Jonjić N, Lučin K.

Acta Histochem. 2014 Jan;116(1):222-9. doi: 10.1016/j.acthis.2013.07.009. Epub 2013 Aug 29.

PMID:
23992637
12.

Prognostic significance of TAZ expression in resected non-small cell lung cancer.

Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu ZH, Xu F, Zhao HY.

J Thorac Oncol. 2012 May;7(5):799-807. doi: 10.1097/JTO.0b013e318248240b.

13.

Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.

Yan CH, Lv M, Li H, Song X, Yan F, Cao S, Ren X.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1371-8. doi: 10.1007/s00432-014-1902-1. Epub 2015 Jan 3.

PMID:
25555465
14.

[Clinicopathological and prognostic significance of ERα and ERβ expression in lung carcinomas: a tissue microarray study].

Yang X, Xue LY, Liu Y, Guo L, Wen P, Lin DM.

Zhonghua Zhong Liu Za Zhi. 2013 Sep;35(9):678-83. Chinese.

PMID:
24332055
15.

Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study.

Zhang L, Hou X, Lu S, Rao H, Hou J, Luo R, Huang H, Zhao H, Jian H, Chen Z, Liao M, Wang X.

Lung Cancer. 2010 Jan;67(1):114-9. doi: 10.1016/j.lungcan.2009.03.017.

PMID:
19376608
16.

Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection.

Sun BS, Li Y, Zhang ZF, You J, Wang CL.

Ann Thorac Surg. 2013 Dec;96(6):1943-51. doi: 10.1016/j.athoracsur.2013.07.089. Epub 2013 Oct 3.

PMID:
24094519
17.

An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.

Wei K, Ye Z, Li Z, Dang Y, Chen X, Huang N, Bao C, Gan T, Yang L, Chen G.

World J Surg Oncol. 2016 Feb 9;14(1):34. doi: 10.1186/s12957-016-0787-7.

18.
19.

Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.

Ostheimer C, Bache M, Güttler A, Reese T, Vordermark D.

BMC Cancer. 2014 Nov 21;14:858. doi: 10.1186/1471-2407-14-858.

20.

Increased osteopontin protein expression may be correlated with poor prognosis in non-small-cell lung cancer: A meta analysis.

Shi SM, Su ZB, Zhao JJ, Yu DJ, Tu JW, Zhu JQ, Zhao JP, Sheng L, Wang SB, Sheng YJ, Chen HJ, Tian JH, Zhang Y, Wang J.

J Cancer Res Ther. 2016 Jan-Mar;12(1):277-82. doi: 10.4103/0973-1482.150362.

Supplemental Content

Support Center